Slide 1: Q4 FY26 Quarterly Investor Presentation & Webinar
ASX Announcement 16 July 2026 Q4 FY26 Quarterly Investor Presentation & Webinar Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to provide below its Q4 FY26 Investor Presentation and Investor Webinar with CEO, Dr Luke Reid presenting. Quarterly Investor Webinar Prese
Slide 2: Building the platform for personalised, microbiome-based healthcare
Q4 FY26 Results Building the platform for personalised, microbiome-based healthcare ASX: MAP 16 JULY 2026 Authorised for release by the Board of Directors 1
Slide 3: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its abs
Slide 4: Q4 FY26 Financial Highlights
Section 1 Q4 FY26 Financial Highlights MICROBA.COM MICROBA LIFE SCIENCES LTD MICROBA.COM EXPECT BETTER © ALL RIGHTS RESERVED EXPECT BETTER
Slide 5: Strong Q4 Core Testing Growth
Quarterly Core Testing Volume 7,000 Strong Q4 Core 6,000 Testing Growth 5,000 Test volume (units) +54% YoY volume. 4,000 Annualised run rate of 3,000 25,000+ 2,000 1,000 0 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Core Testing includes Microbiome Explorer and MetaPanel across Australia and the United
Slide 6: Strong FY26 Core Testing Growth
Annual Core Testing Volume & Revenue 25,000 $9.0M $8.0M 20,000 $7.0M Strong FY26 Core $6.0M Testing Growth Test volume (units) 15,000 Revenue ($) $5.0M +78% YoY volume. $4.0M 10,000 $3.0M +92% YoY revenue. $2.0M 5,000 $1.0M 0 $0.0M FY2024 FY2025 FY2026 Total Core Tests (units) Total Revenue ($) Core
Slide 7: Strong FY26 Continuing product growth
Annual Continuing & Discontinued Product Revenue $18.0M $16.0M Strong FY26 Continuing $14.0M product growth $12.0M Revenue ($) $10.0M +53% YoY Continuing revenue. $8.0M $6.0M -72% YoY Discontinued revenue. $4.0M $2.0M $0.0M FY2024 FY2025 FY2026 Continuing Discontinued Continuing products includes Mi
Slide 8: Q4 FY26 Business Highlights
Section 2 Q4 FY26 Business Highlights MICROBA.COM MICROBA LIFE SCIENCES LTD MICROBA.COM EXPECT BETTER © ALL RIGHTS RESERVED EXPECT BETTER
Slide 9: Key Highlights
Sub-Section 2.1 Key Highlights 8
Slide 10: Growing key enterprise accounts in Australia
Growing key enterprise accounts in Australia Australia – Enterprise Key Account Growth 6,000 45 • In Australia, adoption has now moved beyond innovators into early adopters, 40 increasingly characterised by enterprise-style 5,000 contracts with healthcare clinics. 35 # Signed Key Accounts 4,000 30 •
Slide 11: Upcoming New Product Release
Upcoming New Product Release New Test Release Targeting release in Q1 FY27 On track to launch GI Navigator, a new category-defining testing product, in September 2026. This product is the culmination of several years of leadership at the forefront of this new diagnostic category. It represents a mea
Slide 12: Diagnostic Results
Sub-Section 2.2 Diagnostic Results 11
Slide 13: Strong growth in Core Test sales and clinical adoption in Australia
Strong growth in Core Test sales and clinical adoption in Australia Core Test Volume Ordering Clinicians & Orders Per Clinician Strong growth in Core Test Volume 25,000 1,800 12.0 • Q4 Microbiome Explorer AU test sales of 1,600 5,311, up 54% vs PCP 10.0 20,000 1,400 • Q4 Microbiome Explorer AU annua
Slide 14: Continued progress in UK market development for Microbiome Explorer
Continued progress in UK market development for Microbiome Explorer Ordering Clinicians Core Test Volume & Orders Per Clinician Progress in UK market development 700 6.0 3,500 • Q4 Microbiome Explorer UK test sales of 825, up 92% vs PCP 3,000 600 5.0 • Q4 Microbiome Explorer UK annualised run- rate
Slide 15: Supplement Results
Sub-Section 2.3 Supplement Results 14
Slide 16: Supplement growth focused on Invivo branded products
Supplement growth focused on Invivo branded products Supplements Supplement Revenue Subscriber Growth $1.6M 1,200 • Invivo Supplements revenue of $0.75m in Q4, up 11% QoQ and up 11% vs PCP $1.4M 1,000 $1.2M • Invivo’s leading supplement PHGG’s unit sales more than doubled to 43,000 units in FY26, up
Slide 17: Therapeutic Partnering
Sub-Section 2.4 Therapeutic Partnering 16
Slide 18: Active partnering for pipeline of therapeutic assets
Active partnering for pipeline of therapeutic assets backed by big-data, preclinical and clinical validation Therapeutic Assets • 5+ years of investment to develop a rich pipeline of live Microba maintains its competitive advantage in human data-driven discovery from the human microbiome and biother
Slide 19: Focus & Catalysts
Sub-Section 2.5 Focus & Catalysts 18
Slide 20: Key areas of focus & catalysts
Key areas of focus & catalysts Corporate Snapshot Break-even ASX Code MAP • Streamlining operations to a structurally lower cost base Market capitalisation1 $28.71m • Full group break-even on run-rate basis in CY2027 Shares on issue 700.31m Diagnostics 52-week low / high1 $0.036 / $0.105 • Australia
Slide 21: Share Purchase Plan
Share Purchase Plan MICROBA.COM MICROBA LIFE SCIENCES LTD EXPECT BETTER © ALL RIGHTS RESERVED
Slide 22: Share Purchase Plan (SPP) Details
Share Purchase Plan (SPP) Details Every new share is offered at $0.05 and includes one free attaching option – on the same terms as the institutional placement. SPP Closing Date –Tuesday 22 July 2026 Key terms Illustrative application amounts Free attaching Offer price $0.05 per new share Applicatio
Slide 23: How to participate in the SPP
How to participate in the SPP Who can participate Key dates Shareholders registered in Australia and New Zealand on the record date, Thursday 11 June 2026. Event Date Record date Thursday, 11 June 2026 How much you can invest Any amount up to a maximum of $30,000, at $0.05 per new share. No brokerag
Slide 24: Timetable
Timetable Event Date Record Date for entitlement to participate in SPP Thursday, 11 June 2026 Voluntary Suspension lifted and announcement to ASX of the Placement and SPP Friday, 12 June 2026 Settlement Date of New Shares (Placement) Wednesday, 17 June 2026 Issue of New Shares (Placement) Thursday,
Slide 25: Contact
Dr Luke Reid Contact Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Chair Laboratory pasquale.rombola@microba.com Princess Alexandra Hospital Woolloongabba QLD Australia 24